Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR 0.0084
0.00 (0.00%)
Aug 13, 2026, 3:39 PM CET
Fidia Revenue
In the year 2025, Fidia had annual revenue of 29.49M EUR with 39.76% growth. Fidia had revenue of 555.00K in the half year ending December 31, 2025, a decrease of -96.93%.
Revenue (ttm)
28.68M
Revenue Growth
-6.74%
P/S Ratio
0.14
Revenue / Employee
209.33K
Employees
146
Market Cap
4.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.49M | 8.39M | 39.76% |
| Dec 31, 2024 | 21.10M | -9.05M | -30.02% |
| Dec 31, 2023 | 30.15M | 5.54M | 22.52% |
| Dec 31, 2022 | 24.61M | 573.00K | 2.38% |
| Dec 31, 2021 | 24.03M | 2.27M | 10.43% |
| Dec 31, 2020 | 21.76M | -26.24M | -54.66% |
| Dec 31, 2019 | 48.00M | -10.91M | -18.52% |
| Dec 31, 2018 | 58.92M | 10.96M | 22.84% |
| Dec 31, 2017 | 47.96M | -11.66M | -19.56% |
| Dec 31, 2016 | 59.62M | -3.71M | -5.86% |
| Dec 31, 2015 | 63.33M | 6.02M | 10.51% |
| Dec 31, 2014 | 57.31M | 11.53M | 25.18% |
| Dec 31, 2013 | 45.78M | -3.94M | -7.93% |
| Dec 31, 2012 | 49.72M | 4.20M | 9.21% |
| Dec 31, 2011 | 45.53M | -3.24M | -6.64% |
| Dec 31, 2007 | 48.76M | 6.64M | 15.76% |
| Dec 31, 2006 | 42.13M | 7.21M | 20.64% |
| Dec 31, 2005 | 34.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Danieli & C. Officine Meccaniche | 3.94B |
| Biesse | 650.82M |
| SIT S.p.A. | 316.17M |
| Tesmec | 273.24M |
| ILPRA | 86.81M |
| Marzocchi Pompe | 37.47M |
| OSAI Automation System | 34.56M |
| Valtecne | 31.33M |
Fidia News
- 2 hours ago - Sagimet Biosciences Gets FDA Clearance For Phase 3 Acne Study - Nasdaq
- 4 hours ago - Belite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027 - Nasdaq
- 9 hours ago - SPRO Looks 14.8% Overvalued on GF Value⢠as FDA Approval Spurs Interest - GuruFocus
- 13 hours ago - Exelixis (EXEL) Q2 2026 Earnings Call Transcript - The Motley Fool
- 13 hours ago - Inovio (INO) Q2 2026 Earnings Call Transcript - The Motley Fool
- 14 hours ago - OraSure (OSUR) Q2 2026 Earnings Call Transcript - The Motley Fool
- 17 hours ago - Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - The Motley Fool
- 19 hours ago - Arbutus Advances Imdusiran; FDA Aligns On Phase 2b Trial Design - Nasdaq